Detalhe da pesquisa
1.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Cancer
; 130(2): 287-299, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37801052
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38153814
3.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36709073
4.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38012435
5.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38060001
6.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Eur J Haematol
; 112(3): 379-391, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37899734
7.
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.
Am J Hematol
; 99(3): 336-349, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38165047
8.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36932983
9.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37354090
10.
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment.
Br J Haematol
; 200(3): 315-322, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36266779
11.
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
Ann Hematol
; 102(6): 1409-1420, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37079068
12.
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Ann Hematol
; 102(6): 1375-1382, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37079069
13.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36319575
14.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Am J Hematol
; 98(11): 1762-1771, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37647134
15.
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Curr Treat Options Oncol
; 24(7): 802-820, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37195587
16.
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
Curr Treat Options Oncol
; 24(12): 1720-1738, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38047977
17.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35363892
18.
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
Br J Haematol
; 198(6): 965-973, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35904979
19.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35137397
20.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033